Lilly to present data for galcanezumab for the prevention of migraine at the American Academy of Neurology (AAN) annual meeting

Eli Lilly and CompanyEli Lilly and Company (NYSE: LLY) will highlight Phase 2 data evaluating galcanezumab for the prevention of migraine at the American Academy of Neurology (AAN) annual meeting, which will take place April 22-28, 2017, in Boston.

Lilly will present four abstracts at AAN, including safety and patient outcomes data for galcanezumab in patients with migraine and factors associated with a reduction in monthly migraine headache days among patients with episodic migraine. Lilly will also highlight findings from U.S. healthcare claims data identifying clinical characteristics and treatment patterns among patients with cluster headache.

Galcanezumab is a once-monthly, subcutaneously injected calcitonin gene-related peptide (CGRP) antibody currently being studied as a potential treatment for the prevention of episodic and chronic migraine and cluster headache. Galcanezumab is a monoclonal antibody specifically designed to bind to and inhibit the activity of CGRP that may prevent or significantly reduce the frequency of monthly migraine headache days in patients with episodic and chronic migraine and cluster headache.

"Migraine and cluster headaches are serious, neurological diseases that have a significant physical and emotional impact on not only people affected, but those with whom they interact at home and at work," said Sheena Aurora, M.D., medical fellow and global launch leader, galcanezumab, Eli Lilly and Company. "Lilly is excited to present these galcanezumab data, which further our understanding of these diseases and support our decades-long effort to develop a targeted, preventive therapy that can bring significant value to patients, including a meaningful reduction in the number of days lost to migraine."

Studies, as well as the dates and times of the data sessions, are highlighted below.

Sunday, April 23 - 4:00-5:30 p.m. ET

P1.181: Clinical Characteristics and Treatment Patterns among Patients with Diagnostic Codes for Cluster Headache in the U.S. Healthcare Claims Data
Presenter: Casey Choong, associate consultant, Eli Lilly & Company, Indianapolis, IN

Monday, April 24 - 5:30-7:00 p.m. ET

P2.164: Hepatic Safety of Galcanezumab in Patients with Migraine: Results of Three Phase 2 Double-Blind Placebo-Controlled Trials
Presenter: Vladimir Skljarevski, M.D., medical fellow, Eli Lilly & Company, Indianapolis, IN
P2.177: Factors Associated with Significant Reduction in Migraine Headache Days: A Post-Hoc Analysis of a Phase 2 Placebo-Controlled Trial in Patients Treated with Galcanezumab
Presenter: Sheena Aurora, M.D., medical fellow and global launch leader, galcanezumab, Eli Lilly & Company, Indianapolis, IN
P2.179: Measures of Functioning Using MSQ v2.1 in Patients with a History of Episodic Migraine and Treated with Galcanezumab or Placebo Injections in a Phase 2 Clinical Trial
Presenter: David Ayer, senior research scientist, Eli Lilly & Company, Indianapolis, IN

Top-line results for galcanezumab for the treatment of migraine are expected in 2017. Lilly plans to submit galcanezumab for regulatory approval for migraine in the second half of 2017.

About Galcanezumab
Galcanezumab is a once-monthly, subcutaneously injected calcitonin gene-related peptide (CGRP) antibody currently being studied as a potential treatment for the prevention of episodic and chronic migraine and cluster headache. Galcanezumab is a monoclonal antibody specifically designed to bind to and inhibit the activity of CGRP that may prevent or significantly reduce the frequency of monthly migraine headache days in patients with episodic and chronic migraine.

About Migraine
Migraine is a painful, neurological disease characterized by recurrent episodes of severe headache, and is often accompanied by other symptoms including nausea, vomiting, sensitivity to light and sound, and changes in vision.(1,2) More than 38 million Americans have migraine, with three times more women affected by migraine compared to men.(1,3) According to the Migraine Research Foundation, healthcare and lost productivity costs associated with migraine are estimated to be as high as $36 billion annually in the United States,(1) yet it remains under-recognized and under-treated, with more than 40 percent of people going undiagnosed.(4)

About Cluster Headache
Cluster headache, often characterized as the most painful of all headaches, is a neurological disease characterized by recurrent, severe headaches on one side of the head, usually behind or around one eye.(2,5) Cluster headaches - commonly known as "attacks" - typically last between 15 minutes to more than two hours and can recur on the same day and occur daily to multiple times a day for weeks or longer, followed by periods of time in which no attacks occur.(5) Cluster headache is classified as "chronic" when attacks occur for more than one year without a remission period, or with remission lasting less than one month.(5)

About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.

1. Headache disorders. World Health Organization website. http://www.who.int/mediacentre/factsheets/fs277/en/. Accessed April 5, 2017.
2. Russo AF. Calcitonin gene-related peptide (CGRP): a new target for migraine. Annual Review of Pharmacology and Toxicology. 2015;55:533-552.
3. Identifying and treating migraine. American Migraine Foundation website. https://americanmigrainefoundation.org/understanding-migraine/identifying-treating-migraine/. Accessed April 19, 2017.
4. Diamond S, Bigal ME, Silberstein S, et al. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Prevalence and Prevention study. Headache. 2007;47(3):355-363.
5. Treatment for cluster headache. American Migraine Foundation website. https://americanmigrainefoundation.org/understanding-migraine/treatment-of-cluster-headache/. Accessed April 19, 2017.

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

Scientists develop new biomimetic formulation for …

Glioblastoma multiforme (GBM) is an aggressive brain cancer with a poor prognosis and few treatment options. New and effective approaches for GBM treatment are therefore ...